Calcitoningene-relatedpeptidemigraine Calcitonin gene-related peptide (CGRP) receptor antagonists, often referred to as gepants, represent a significant advancement in the management of migraine headaches. These innovative medications work by blocking the activity of CGRP, a molecule implicated in the pain and inflammation associated with migraine attacks. Unlike older treatments that primarily address symptoms, CGRP receptor antagonists target a specific biological pathway involved in migraine, offering a novel approach to both acute treatment and prevention.
Calcitonin gene-related peptide (CGRP) is a neuropeptide found throughout the nervous system, with a notable presence in trigeminal nerves that play a crucial role in migraine pathophysiology. During a migraine attack, CGRP is released and can cause vasodilation of blood vessels in the brain and promote neurogenic inflammation, contributing to the throbbing pain characteristic of migraines. Targeting this pathway offered a logical strategy for developing new migraine therapies.作者：IA Mulder·2020·被引用次数：133—Objective:Calcitonin gene-related peptide(CGRP) pathway inhibitors are emerging treatments for migraine.CGRP-mediated vasodilation is, however, a critical ...
The development of CGRP receptor antagonists has led to a new class of oral medications known as gepants作者：F Xu·2019·被引用次数：31—Research has indicated thatcalcitonin gene-related peptide (CGRP) receptor antagonistscan be effective in the acute treatment of migraine.. These small molecules are designed to selectively bind to and block the CGRP receptor, thereby preventing CGRP from exerting its effects. This mechanism of action is distinct from older migraine treatments and has shown efficacy in both treating acute migraine attacks and, for some agents, preventing them.
Key gepants that have emerged include ubrogepant, rimegepant, and atogepant. These medications offer patients new options for managing their migraines, with some demonstrating the ability to effectively abort acute attacks and others showing promise in reducing migraine frequency. The oral administration of these drugs provides a convenient and accessible treatment modality for many individuals suffering from this debilitating condition.
While gepants represent a significant breakthrough, they are not the only form of CGRP-targeted therapy.作者：IM Bell·2014·被引用次数：90—The present review describes the discovery and development of these new antimigraine agents and highlights the challenges of identifying orally ... Another important class of drugs are monoclonal antibodies that target either the CGRP peptide itself or the CGRP receptor. These therapies, such as erenumab, galcanezumab, fremanezumab, and eptinezumab, are typically administered via injection and are primarily used for migraine prevention.
The distinction between gepants and monoclonal antibodies lies in their molecular structure, route of administration, and primary indication.Fragment-Based Discovery of an Oral Calcitonin Gene ... Gepants are small molecules taken orally for acute treatment and sometimes prevention, while monoclonal antibodies are larger protein-based molecules administered by injection, predominantly for preventive therapy. Both approaches, however, share the common goal of disrupting the CGRP pathway to alleviate migraine symptoms.
Research and clinical trials have highlighted the efficacy of CGRP receptor antagonists in treating acute migraine attacks. Studies have shown that these medications can be effective in aborting migraine pain and associated symptoms, offering relief to many patients who may not have responded adequately to previous treatments. Furthermore, the development of gepants for preventive therapy signifies a crucial step forward in managing chronic migraineLipidated Calcitonin Gene-Related Peptide (CGRP) ....
The exploration of CGRP receptor antagonists is ongoing, with continued research into their long-term safety, efficacy, and potential for treating other conditions where CGRP may play a role. The advent of these therapies marks a new era in headache medicine, providing targeted and often highly effective solutions for individuals living with the burden of migraineCalcitonin Gene Related Peptide Receptor Antagonist. As research progresses, the landscape of migraine treatment is expected to continue evolving, offering greater hope and improved quality of life for patients.
Join the newsletter to receive news, updates, new products and freebies in your inbox.